3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lymphoma, Non-Hodgkin
4
Lymphoma
4
Leukemia
4
Vomiting
3
Neoplasms
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Lymphoma, B-Cell
3
Hodgkin Disease
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Nausea
2
Myelodysplastic Syndromes
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Leukemia, Hairy Cell
2
Kidney Neoplasms
2
Hematologic Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma in Situ
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Alveolar Soft Part
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
pembrolizumab
120
Cisplatin
26
Carboplatin
24
Paclitaxel
21
Docetaxel
17
lenvatinib
15
Pemetrexed
12
Fluorouracil
12
Saline Solution
11
Capecitabine
10
epacadostat
8
Oxaliplatin
7
Gemcitabine
7
Leucovorin
5
Cetuximab
5
130-nm albumin-bound paclitaxel
5
olaparib
4
enzalutamide
4
Irinotecan
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
Prednisone
3
Dexamethasone
3
Radiotherapy
2
Ipilimumab
2
Glucose
2
Etoposide
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Diphenhydramine
×
Clear all
NCT04165096
2026-05-13
MK-3475-01C
Merck Sharp & Dohme LLC
Phase 2
Completed
128 enrolled
14 charts